Savara (SVRA) Tops Q2 EPS by 8c

Savara (NASDAQ: SVRA) reported Q2 EPS of ($0.16), $0.08 better than the analyst estimate of ($0.24).

“With a final design for IMPALA 2, we are working diligently on study preparations and expect it to start in the first quarter of next year,” said Rob Neville, Chief Executive Officer, Savara. “Building on the learnings from the first IMPALA study, and following constructive discussions with the regulatory agencies, we are confident in the study design and believe IMPALA 2 will effectively measure the potential efficacy and safety of Molgradex to treat aPAP.”

For earnings history and earnings-related data on Savara (SVRA) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Worthington Industries (WOR) Tops Q1 EPS by 7c
• KB Home (KBH) Tops Q3 EPS by 16c